IN THE CLAIMS

1. (currently amended) A pharmaceutical composition comprising a ~~V~~virally-safe plasma-derived Factor VIII ~~composition, characterized in that it is obtained after~~ obtained by filtering through a nanometric filter ~~of nominal~~having a pore size of 13~~15+2~~ nm to 25~~23+2~~ nm, wherein the filtrate comprises the virally-safe plasma derived Factor VIII solution having a ~~and in that its~~ von Willebrand Factor (vWF) content ~~is~~ of 15 % or less of decamers and higher multimers.

2. (currently amended) The pharmaceutical ~~C~~composition ~~as in~~of claim 1, ~~characterized in that~~wherein the titre reduction factor of a virus ~~of~~ having a size of 24 nm to 30~~27+3~~ nm is 4 log or more, ~~preferably 5 log, advantageously~~ 6 log as compared with the solution before filtration.

3. (currently amended) The ~~P~~harmaceutical composition ~~as in either~~ of claim~~s~~ 1, ~~and 2~~which is in the form of an injectable solution ~~via intravenous, intramuscular or subcutaneous route~~.

4. (currently amended) A ~~M~~method for testing the viral safety of a plasma-derived Factor VIII composition obtained by nanometric filtering, comprising ~~a~~ the step ~~consisting~~ of determining the residual content of high multimerisation vWF.

5. (currently amended) The ~~M~~method ~~as in~~of claim 4, wherein a determination of the residual content ~~characterized in that the detection~~ of less than 15 % vWF decamers and higher multimers after nanometric filtration indicates that said composition is virally safe.

6. (currently amended) The ~~M~~method ~~as in~~of claim 5, wherein a determination of the residual content ~~characterized in that the detection~~ of less than 15 % vWF decamers and higher

multimers is correlated with a reduction factor of virus titre of at least 4 log.

7. (currently amended) A ~~M~~method for preparing a virally safe Factor VIII solution, the method comprising:

~~a~~ filtering a solution ~~step~~ through nanometric filters having a ~~of nominal~~ pore size of 13~~15±2~~ nm to 25~~23±2~~ nm;~~,~~ and

~~an~~ assaying the filtrate to determine the residual content of high-multimerization vWF ~~step of von Willebrand Factor (vWF) decamers and higher multimers~~.

8. (currently amended) The ~~M~~method ~~as in~~of claim 7, ~~characterized in that~~wherein the step of assaying the filtrate ~~step consists of~~includes verifying that the content of vWF decamers and higher multimers is 15 % or less.

9. (currently amended) The ~~M~~method ~~as in~~of claim 7, ~~characterized in that~~wherein a vWF decamer and higher multimer content of 15 % or less indicates that the titre reduction factor of a virus ~~of~~ having a size of 24 nm to 30~~27±3~~ nm is 4 log or more, ~~preferably 5 log or~~to about 6 log as compared with the solution before filtration.

10. (canceled)

11. (new) A pharmaceutical composition comprising virally-safe plasma-derived Factor VIII having a von Willebrand Factor (vWF) contents of about 15% of less or less decamers and higher multimers.

12. (new) The pharmaceutical composition of claim 11 for use in treating diseases related to blood coagulation.

13. (new) The pharmaceutical composition of claim 12 for use in treating haemophilia.

14. (new) The pharmaceutical composition of claim 1, wherein the titre reduction factor of a virus having a size of 24 nm to 30 nm is 5 log as compared with the solution before filtration.

15. (new) The pharmaceutical composition of claim 1, wherein the titre reduction factor of a virus having a size of 24 nm to 30 nm is 6 log as compared with the solution before filtration.

16. (new) The method of claim 7, wherein a vWF decamer and higher multimer content of 15 % or less indicates that the titre reduction factor of a virus having a size of 24 nm to 30 nm is 5 log ore more, to about 6 log as compared with the solution before filtration.

17. (new) The method of claim 7, wherein a vWF decamer and higher multimer content of 15 % or less indicates that the titre reduction factor of a virus having a size of 24 nm to 30 nm is 6 log ore more, to about 6 log as compared with the solution before filtration.

18. (new) A pharmaceutical composition comprising a virally-safe plasma-derived Factor VIII having a von Willebrand Factor content of 15% or less of decamers and higher mutimers.